Why 30% discount is that the prevailing discount on AB rated generics? same question about 40% market share. The Duke university report did not show anything near those numbers.
Why do you have to wait till break even before you sell. If you think this company is going nowhere sell at a loss and recoup the money where you see a better opportunity:
"The complete response letter from the FDA provided revisions to labelling and cited minor deficiencies. "
I assume this means there are no major issues?
Antares Pharma, Inc. (ATRS) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter regarding the Abbreviated New Drug Application (ANDA) for Sumatriptan Injection USP for the acute treatment of migraine. The complete response letter from the FDA provided revisions to labelling and cited minor deficiencies. If approved, Sumatriptan Injection USP would represent the Company’s first ANDA approval and second device approved from the VIBEX® auto injector platform. As previously disclosed, Teva Pharmaceutical Industries, Ltd. would distribute the product and share the profits equally with Antares Pharma.
Eamonn P. Hobbs, President and Chief Executive Officer, stated, “We are pleased with the feedback received from the FDA in the complete response letter. The FDA has outlined the steps necessary to support approval of the ANDA, and we plan to work closely with the Agency on a response.”
And your reading comprehension is not exactly up to scratch either. You have still not answered the question that td posted and I repeated. As a matter of fact I don't think you have ever answered a question that you don't like the real answer to, but instead attack the poster or post something that has absolutely nothing to do with the question asked. Your refusal to answer questions regarding your statements must be because you don't comprehend or is there another reason?
If you consider that the 13 reps(I think it was 13) that was not taken on for the in-house program probably had not been replaced and certainly would not have been up to speed in the case that they had been replaced. Not to mention that probably one third of December was lost to Holidays.
2295 is a very respectable number for December. It's a pity that drroid is not posting the numbers anymore. Hopefully he will restart or someone else will take up posting the numbers.
Good find hofno the whole presentation is good
Sentiment: Strong Buy
andre you are really something......
td did not concede anything.
Td Posted this for you.
" If you disagree with this, please make reference to similar "pharma" court cases where settlements were reached for generic product launches, but lawsuits still persisted beyond the settlement date. If such instances exist, please show examples - we'll go from there. "
Can you reply or are you to busy making up your own stuff.
The brainless individual who is incapable of creating his own unique ID. Even if it's his fourth ID on this board.
Report this user as an imposter.
Got this on my Phone APP
Antares Pharma Inc Price Target Update
by Thomas Lindt on January 20, 2015 0
Antares Pharma Inc (NASDAQ:ATRS): 3 Analyst have given the stock of Antares Pharma Inc (NASDAQ:ATRS) a near short term price target of $5.5. The standard deviation reading, which is a measure by which the stock price is expected to swing away from the mean estimate, is at $1.32. The higher price target estimate is at $7 while the lower price estimates are fixed at $4.
Many Analysts from different Brokerage Firms have commented on the company rating and price targets.Antares Pharma Inc (NASDAQ:ATRS) has lost 9.74% during the past week and dropped 8.37% in the past 4 weeks. The shares are however, marginally negative as compared to the S&P 500 for the past week with a loss of 8.6%. Antares Pharma Inc (NASDAQ:ATRS) has underperformed the index by 6.04% in the past 4 weeks. Investors should watch out for further signals and trade with caution.
Antares Pharma Inc (NASDAQ:ATRS) reported a drop of 14% or 1,551,099 shares in its short interest. The short figure came in at 8.2% of the total floats. The average daily volume of 1,072,461 shares suggests that the days to cover 9,567,164 short positions, as on December 31,2014, will be 9. On December 15,2014, the short interest was 11,118,263 shares.
Antares Pharma Inc (NASDAQ:ATRS) witnessed a decline in the market worth as its shares dropped 2.07% or 0.05 points. After the session commenced at $2.4, the stock could not gain beyond $2.41 while it hit a deep low of $2.31. With the volume soaring to 933,363 shares, the last trade was called at $2.36. The stock had ended the previous trading session at $2.41. The company has a 52-week high of $4.97. The company has a market cap of $311 million and there are 131,684,000 shares in outstanding. The 52-week low of the share price is $1.82.